ANUHPHR

Anuh Pharma financials

Market cap
₹949 Cr
Sector
Healthcare

What Anuh Pharma does

Anuh Pharma manufactures Active Pharmaceutical Ingredients (bulk drugs) at a single EU-GMP/WHO-prequalified facility in Tarapur, Maharashtra, and is one of the largest producers of first-generation erythromycin (macrolide) salts and anti-TB APIs in India. It also makes anti-malarial, anti-diabetic, anti-bacterial, anti-histamine, anti-gout and corticosteroid APIs, supported by an in-house R&D facility at Mahape, Navi Mumbai. It earns by selling these APIs to pharmaceutical formulators and distributors both domestically and through export marketing partnerships across regulated and emerging markets.

Segments

  • Macrolides / Erythromycin salts
  • Anti-TB APIs
  • Anti-malarial APIs
  • Corticosteroids
  • Anti-diabetic APIs
  • Anti-bacterial / Antibiotic APIs
Manufacturing plants
1 facility at Tarapur, Maharashtra (11,400 sq. mtrs; 9 API blocks + 2 intermediate blocks)
Installed API capacity
2,400 MTPA (metric tons per annum)
Annual production volume
1,733 MT (FY26)
R&D facility
10,000 sq. ft. at Mahape, Navi Mumbai; 16 scientists
Export markets
72 countries (FY26)
Marketing partner customers
360 (FY26)
Founded 1960Headquarters Mumbai, Maharashtra, India Company website

Quarterly results

Q1 FY27: revenue up 4.3%, net profit up 37.5% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue166 160 198 186 186 +12%197 +23%202 +2%194 +4%
EBITDA17 15 19 10 12 −29%19 +27%20 +5%16 +60%
Net profit15 10 12 8 8 −47%13 +30%12 +0%11 +38%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance +6.6% 1Y

₹70.0₹80.0₹90.0Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹88.96 on 10 Sept 2025 → ₹94.86. High ₹96.74 (9 Sept 2026), low ₹67 (30 Mar 2026).

Financials, as filed

Revenue grew 13.5% a year over 3 years, FY23 to FY26. Operating margin narrowed to 7.9%.

Year endingFY23FY24FY25FY26
Revenue₹527 Cr₹647 Cr₹662 Cr₹771 Cr
Operating profit₹51 Cr₹75 Cr₹62 Cr₹61 Cr
Operating margin9.6%11.6%9.4%7.9%
Interest₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Depreciation₹9 Cr₹8 Cr₹9 Cr₹12 Cr
Net profit₹36 Cr₹60 Cr₹47 Cr₹41 Cr
Net margin6.9%9.3%7.1%5.3%
Cash from operations₹54 Cr₹13 Cr₹37 Cr₹-3 Cr
Free cash flow₹52 Cr₹8 Cr₹17 Cr₹-11 Cr
ROCE19.0%26.0%17.0%15.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹25 Cr₹25 Cr₹25 Cr₹25 Cr₹50 Cr₹50 Cr
Reserves₹166 Cr₹189 Cr₹216 Cr₹266 Cr₹277 Cr₹302 Cr
Borrowings₹14 Cr₹4 Cr₹1 Cr₹3 Cr₹0 Cr₹0 Cr
Other liabilities₹128 Cr₹129 Cr₹163 Cr₹152 Cr₹182 Cr₹205 Cr
Total liabilities₹333 Cr₹347 Cr₹405 Cr₹446 Cr₹509 Cr₹557 Cr
Fixed assets₹71 Cr₹61 Cr₹53 Cr₹49 Cr₹61 Cr₹57 Cr
Capital work in progress₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹1 Cr₹0 Cr
Investments₹31 Cr₹43 Cr₹91 Cr₹97 Cr₹71 Cr₹84 Cr
Other assets₹230 Cr₹243 Cr₹261 Cr₹300 Cr₹376 Cr₹416 Cr
Total assets₹333 Cr₹347 Cr₹405 Cr₹446 Cr₹509 Cr₹557 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, promoters added +1.88 pp while the public trimmed −1.85 pp. The shareholder count grew 13% to 27,484.

Promoters
71.8%
FIIs
0.0%
Public
28.2%

Since Jun 2025

  • Promoters +1.88 pp
  • Public −1.85 pp
  • FIIs −0.03 pp

How it drifted, 12 quarters

Over this window the public fell from 29.4% to 28.2% — −1.2 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 70.6%, Public 29.4%.Dec '23: Promoters 69.9%, Public 30.1%.Mar '24: Promoters 69.9%, FIIs 0.0%, DIIs 0.1%, Public 30.0%.Jun '24: Promoters 69.9%, FIIs 0.0%, Public 30.1%.Sep '24: Promoters 69.9%, FIIs 0.0%, Public 30.1%.Dec '24: Promoters 69.9%, FIIs 0.0%, Public 30.1%.Mar '25: Promoters 69.9%, FIIs 0.0%, Public 30.0%.Jun '25: Promoters 69.9%, FIIs 0.0%, Public 30.0%.Sep '25: Promoters 71.8%, Public 28.2%.Dec '25: Promoters 71.8%, Public 28.2%.Mar '26: Promoters 71.8%, FIIs 0.1%, Public 28.1%.Jun '26: Promoters 71.8%, FIIs 0.0%, Public 28.2%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 0 holders trimming and 1 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of Anuh Pharma above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Bharti Bipin Shah 19.43%unchanged
Prafulla Lalit Shah 14.47%unchanged
Bipin Nemchand Shah - 2 8.48%+2.27 pp
Bharat Nemchand Shah 3.73%unchanged
Gaurav Satish Shah 3.19%unchanged
Mrudula Jayantilal Shah 2.33%unchanged
Vivek Bipin Shah 2.33%unchanged
Ritesh Bipin Shah 2.31%unchanged
Dina Satish Shah 2.22%unchanged
Samir Jayantilal Shah 1.72%unchanged
Michael Dsouza 1.10%unchanged
Kinjal Siddharth Jhaveri 0.81%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

What the price assumes

Expensive

To justify its price of ₹95, this stock must grow earnings at 15% every year for 7 years. Our analysis caps realistic growth at ~4%. At that growth it is worth ₹55 — downside of 42%.

Growth the price implies
14.5% a year
for 7 years, fading to 4%
It has actually compounded at
4.2% a year
net profit, FY23–FY26 · EPS 4.3%
The gap
0.1 pp
-42% downside if it only repeats history
Price today ₹94.86 Value at the reference growth ₹54.94

Change the assumptions yourself →

Learn to analyse Anuh Pharma

Guides on how to read this kind of business and the numbers that matter.